Australian Gonococcal Surveillance Programme Annual Report, 2018
DOI:
https://doi.org/10.33321/cdi.2020.44.4Keywords:
antimicrobial resistance, disease surveillance, gonococcal infection, Neisseria gonorrhoeaeAbstract
The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in clinical isolates of Neisseria gonorrhoeae from all states and territories since 1981. In 2018, there were 9,006 clinical isolates of gonococci from public and private sector sources tested for in vitro antimicrobial susceptibility by standardised methods. This was the highest annual total of isolates tested since the inception of the AGSP. The current treatment recommendation for gonorrhoea, for the majority of Australia, remains dual therapy with ceftriaxone and azithromycin. Decreased susceptibility to ceftriaxone (minimum inhibitory concentration (MIC) value ≥0.06 mg/L) was found nationally in 1.73% of isolates. The highest proportions were reported from Tasmania and non-remote Western Australia (7.3% and 2.1% respectively). In 2018 two extensively drug-resistant isolates were reported from Queensland patients. These two isolates, with ceftriaxone MIC values of 0.50 mg/L, high-level resistance to azithromycin (MIC ≥ 256 mg/L), and resistance to penicillin and ciprofloxacin were identified and reported to the World Health Organization as isolates of international significance. Resistance to azithromycin (MIC value ≥1.0 mg/L) was found nationally in 6.2% of isolates, lower than the 9.3% reported in 2017, but more than double the proportion reported in 2015 (2.6%). The highest proportions were reported from the Australian Capital Territory (8.7%), Victoria (8.3%), and New South Wales (6.5%). High-level resistance to azithromycin (MIC value ≥256 mg/L) was reported in nine isolates nationally in 2018: four from New South Wales, three from Victoria, and two from Queensland.
The proportion of isolates resistant to penicillin in non-remote Australia ranged from 8.8% in non-remote Northern Territory to 44.1% in South Australia. In remote Northern Territory penicillin resistance rates remain low (1.9%), and higher in remote Western Australia (6.5%).
The proportion of isolates resistant to ciprofloxacin in non-remote Australia ranged from 10.3% in non-remote Northern Territory to 48.3% in South Australia. Ciprofloxacin resistance rates remain comparatively low in remote Northern Territory (1.9%) and remote Western Australia (4.6%).
Downloads
References
Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2013.
Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: Annual Surveillance Report 2018. Sydney: Kirby Institute, UNSW Sydney, 2018. Available from: https://kirby.unsw.edu.au/sites/default/files/kirby/report/KI_Annual-Surveillance-Report-2018.pdf.
Lahra MM, Martin I, Demczuk W, Jennison AV, Lee KI, Nakayama SI et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerg Infect Dis. 2018;24(4). https://doi.org/10.3201/eid2404.171873.
Lahra MM, Enriquez R. Australian Gonococcal Surveillance Programme Annual Report, 2016. Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00013-1.
Australasian Sexual Health Alliance. Australian STI management guidelines for use in primary care: Gonorrhoea. [Internet.] Australasian Sexual Health Alliance, 2018. Available from: http://www.sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea.
Lahra MM, Ward A, Trembizki E, Hermanson J, Clements E, Lawrence A et al. Treatment guidelines after an outbreak of azithromycin resistant Neisseria gonorrhoeae in South Australia. Lancet Infect Dis. 2017;17(2):133–4.
Family Planning Association. Sexually transmitted infections factsheet. [Internet.] United Kingdom: Family Planning Association, 2016. Available from: https://www.fpa.org.uk/factsheets/sexually-transmitted-infections.
Centers for Disease Control and Prevention. 2016 Sexually Transmitted Diseases Surveillance Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2017.
European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – Gonorrhoea. [Internet.] Stockholm: European Centre for Disease Prevention and Control, 2016. Available from: https://ecdc.europa.eu/sites/portal/files/documents/Gonorrhoea%20AER_0.pdf .
Government of Canada. Gonorrhea. [Internet.] Ottawa: Government of Canada, 2017. Available from: https://www.canada.ca/en/public-health/services/diseases/gonorrhea.html.
Goire N, Freeman K, Tapsall JW, Lambert SB, Nissen MD, Sloots TP et al. Enhancing gonococcal antimicrobial resistance surveillance: a real-rime PCR assay for detection of penicillinase-producing Neisseria gonorrhoeae by use of noncultured clinical samples. J Clin Microbiol. 2011;49(2):513–8.
Speers DJ, Fisk RE, Goire N, Mak DB. Non-culture Neisseria gonorrhoeae molecular penicillinase production surveillance demonstrates the long-term success of empirical dual therapy and informs gonorrhoea management guidelines in a highly endemic setting. J Antimicrob Chemother. 2014;69(5):1243–7.
World Health Organization (WHO). Report on global sexually transmitted infection surveillance 2018. Geneva: WHO, 2018.
Lahra MM, Lo YR, Whiley DM. Gonococcal antimicrobial resistance in the Western Pacific Region. Sex Transm Infect. 2013;89(Suppl 4):iv19–23.
Tapsall JW, Limnios EA, Murphy D. An analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997 – 2006. J Antimicrob Chemother. 2008;61(1):150–5.
Tapsall J, World Health Organization (WHO) Anti-Infective Drug Resistance Surveillance and Containment Team. Antimicrobial resistance in Neisseria gonorrhoeae. Switzerland: World Health Organization, 2001. Available from: https://apps.who.int/iris/handle/10665/66963.
World Health Organization (WHO), Department of Reproductive Health and Research. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Switzerland: WHO, 2012.
Bell SM, Pham JN, Rafferty DL, Allerton JK. Antibiotic susceptibility testing by the CDS method: A manual for medical and veterinary laboratories. 8th ed. Kogarah, NSW: South Eastern Area Laboratory Services, 2016.
Tapsall JW. Use of a quality assurance scheme in a long-term multicentric study of antibiotic susceptibility of Neisseria gonorrhoeae. Genitourin Med. 1990;66(1):8–13.
Australian Government Department of Health. National Notifiable Diseases Surveillance System. [Internet.] Canberra: Australian Government, Department of Health, 2018. [Accessed 16 Apr 2018.] Available from: http://www9.health.gov.au/cda/source/cda-index.cfm .
Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance (AMR) surveillance for public health purposes. J Antimicrob Chemother. 2009;63(6):1142–51.
Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55(7):3538–45.
Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: Novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56(3):1273–80.
Cámara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012;67:1858–60.
Lahra MM, Ryder N, Whiley DM. A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med. 2014;371(19):1850–1.
European Centre for Disease Prevention and Control. Rapid Risk Assessment: Extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia – 7 May 2018. [Internet.] Stockholm: ECDC, 2018.
Jennison AV, Whiley D, Lahra MM, Graham RM, Cole MJ, Hughes G et al. Genetic relatedness of ceftriaxone-resistant and high-level azithromycin resistant Neisseria gonorrhoeae cases, United Kingdom and Australia, February to April 2018. Euro Surveill. 2019;24(8): https://doi.org/10.2807/1560-7917.ES.2019.24.8.1900118.
Stevens K, Zaia A, Tawil S, Bates J, Hicks V, Whiley D et al. Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Australia. J Antimicrob Chemother. 2015;70(4):1267–8.
Whiley DM, Lahra MM, Unemo M. Prospects of untreatable gonorrhea and ways forward. Future Microbiol. 2015;10(3):313–6.
Lahra MM, Enriquez RP. Australian Gonococcal Surveillance Programme, 1 July to 30 September 2016. Commun Dis Intell Q Rep. 2017;41(1):E109–10.
Unemo M. Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
